agn-151587
Nucleic acidexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jun 3, 2019 (NCT03872479)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Centrosomal protein of 290 kDaSupplementation
CEP290 supplementation
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03872479 | Phase 1/Phase 2 (Phase 2) | Jun 3, 2019 | Allergan, Editas Medicine, Inc. |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Allergan | For profit | 1 | 1 | 1 | 2019 |
| Editas Medicine, Inc. | For profit | 1 | 0 | 1 | 2019 |
2 organizations
Page 1 / 1